β-Carboline Derivatives Tackling Malaria: Biological Evaluation and Docking Analysis

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• Increasing antimalarial drug resistance necessitates novel therapeutic compounds.
• The β-carboline scaffold is a recognized structural motif in antimalarial drug development.

Purpose of the Study:

• To evaluate the antimalarial potential of a specific β-carboline derivative, compound 9a.
• To assess compound 9a's efficacy both as a monotherapy and in combination with artesunate.

Main Methods:

• In vitro testing against Plasmodium falciparum strains (3D7 and RKL-9).
• In vivo studies using Plasmodium berghei in mice, including monotherapy and combination therapy with artesunate.
• Assessing cytotoxicity, selectivity index, median effective dose (ED50), and chemosuppression.

Main Results:

• Compound 9a exhibited potent in vitro activity (IC50 < 1 μg/mL) and low cytotoxicity (CC50 > 640 μg/mL) with a selectivity index >10.
• In vivo monotherapy showed considerable antimalarial activity (ED50 = 27.74 mg/kg).
• Combination therapy with artesunate achieved 99.69% chemosuppression and prolonged survival in mice.

Conclusions:

• Compound 9a is a promising antimalarial candidate with significant in vitro and in vivo efficacy.
• The β-carboline derivative shows potential for combination therapy, addressing drug resistance challenges.
• Further investigation into compound 9a is warranted for its development as a novel antimalarial drug.